PEDIATRICS· 2026Q1
Dual Remission of Atopic Dermatitis and Frequently Relapsing Nephrotic Syndrome With Dupilumab
- 0citations
- Q1SCImago
- 2026year
Short summary
Dupilumab (300 mg every 2 weeks) achieved sustained remission in a 9-year-old girl with both atopic dermatitis (AD) and frequently relapsing nephrotic syndrome, allowing discontinuation of corticosteroids and tacrolimus for nearly 2 years.
AI-generated from the title and abstract; the full text is not read.
Key points
- Dupilumab treatment led to complete clearance of atopic dermatitis lesions.
- Nephrotic syndrome remission was sustained for nearly 2 years.
- Corticosteroids and tacrolimus were discontinued within 2 months of starting dupilumab.
- The patient experienced no relapses of either condition after treatment initiation.
AI-generated from the title and abstract; the full text is not read.
Abstract
Nephrotic syndrome in children and atopic dermatitis (AD) share a common type 2 inflammatory substrate driven by interleukin (IL)-4 and IL-13 dysregulation. We report the case of a 9-year-old girl with AD and frequently relapsing steroid-sensitive nephrotic syndrome. Given the broad atopic phenotype and increasing relapse frequency despite dual immunosuppressive therapy, dupilumab 300 mg every 2 weeks was introduced. The patient achieved rapid and complete clearance of cutaneous lesions alongside sustained complete remission of nephrotic syndrome, maintained over nearly 2 years. Both corticosteroids and tacrolimus were fully discontinued within 2 months of dupilumab initiation, with no subsequent relapse of either condition. This case supports the hypothesis that dupilumab may represent an effective steroid-sparing therapeutic option in children with nephrotic syndrome arising in an atopic context.
The authors' abstract, as published at the source. PEDIATRICS, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Dermatology
DermatologyMedicine